For example, BRCA1 can inhibit progesterone receptor (PR) activity in the PR-positive human breast cancer cell line T47D [17, 18] and repress estrogen receptor-alpha activity in MCF-7 cells [19]. BRCA1 may also be a potential regulator of the insulin-like growth factor 1
receptor in human breast cancer cell line HCC1937 [20]. However, to date, there have been few reports about the interactions between BRCA1 and EGFR in ovarian cancer. Conclusions The present study supports the theory that the EGFR gene is also a physiologically relevant downstream target for BRCA1. The data presented in this study emphasize the convergence of the EGFR-mediated cell proliferation QNZ clinical trial pathway and BRCA1-mediated antitumor mechanism. Clarifying the complex interactions between BRCA1 and EGFR signaling pathways at the transcriptional, posttranscriptional, and epigenetic levels may improve our understanding of the basic molecular mechanism of ovarian cancer. Acknowledgements This work was supported by the 973 Program of China (No. 2011CB933504), Natural Science Foundation of China (No. 81071072) and the Higher Specialized
Research Fund for Doctoral Program of Ministry of Education of China (No. 20122104110027). Electronic Compound C molecular weight supplementary material Additional file 1: Table S1: Clinical characteristics for the 28 BRCA1-mutated Small molecule library serous ovarian cancer patients. Table S2: Clinical characteristics for the 23 BRCA2-mutated serous ovarian cancer patients. (PDF 82 KB) Additional file 2: Cell proliferation after the overexpression of BRCA1, or knockdown of BRCA1 plus erlotinib or not. (PDF 749 KB) Additional file 3: Supplementary
methods. (PDF 56 KB) Additional file 4: Univariate analysis of overall survival for ovarian cancer patients with low BRCA1-high EGFR expression and high BRCA1-low EGFR expression. (PDF 381 KB) References 1. Kim A, Ueda Y, Naka T, Enomoto T: Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Montelukast Sodium Res 2012, 31:14.PubMedCentralPubMedCrossRef 2. Werner H, Bruchim I: IGF-1 and BRCA1 signalling pathways in familial cancer. Lancet Oncol 2012, 13:e537-e544.PubMedCrossRef 3. Gui T, Shen K: The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol 2012, 36:490–496.PubMedCrossRef 4. Sheng Q, Liu J: The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 2011, 104:1241–1245.PubMedCentralPubMedCrossRef 5. Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, Sensi M, Canevari S, Tomassetti A: Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 2012, 31:4139–4149.PubMedCrossRef 6. Bull Phelps SL, Schorge JO, Peyton MJ, Shigematsu H, Xiang LL, Miller DS, Lea JS: Implications of EGFR inhibition in ovarian cancer cell proliferation. Gynecol Oncol 2008, 109:411–417.PubMedCrossRef 7.